Thus, these results provide a clue on a new mechanism of action of RT in combination with CCR2/5i that, through an increased transcription of CCL17 and CCL22, leads to increased effector T cell infiltration into the tumor and improved T cell function (Fig. 6 C). The gene discussed is CCL17; the disease is neoplasm.